Ahead of its mega-IPO, SpaceX revealed healthcare ambitions in its SEC filing, highlighting Starlink's role in improving remote healthcare access in underserved areas. The company also envisions manufacturing pharmaceuticals in orbit, leveraging microgravity to enhance drug properties, a concept tested by other pharma firms. Additionally, SpaceX sees AI as a key tool for accelerating scientific discovery and medical diagnosis, though its AI chatbot Grok has faced challenges in providing accurate health advice. These moves signal SpaceX's potential to expand beyond aerospace into healthcare innovation.
Shares of Intuitive Machines surged 10% despite missing Q2 revenue and earnings estimates, driven by a record backlog of $1.8 billion and strong bookings. Virgin Galactic also gained 10% after bouncing back from a recent 8% drop caused by a delay in ...
Northrop Grumman's new Mission Robotic Vehicle (MRV) and Mission Extension Pods (MEPs) are advancing satellite life extension by autonomously docking and refueling satellites in orbit. Recently, an older Mission Extension Vehicle (MEV) detached from ...
Virgin Galactic will release its Q2 2026 earnings on August 12, with analysts expecting a loss of $0.64 per share and revenues around $127,000. Despite ongoing profitability challenges, including a negative P/E ratio and high debt, the company's stoc...
SpaceX shares dropped 5% to $131.78 after a recent 11% rally driven by an Argus upgrade faded. The decline reflects investor caution over the company's heavy capital spending on AI infrastructure, including plans for orbital data centers, and the imp...
